Dirac Biosciences
ActiveSummary
The computed 12-month bankruptcy probability of Dirac Biosciences is 19.1% (high). The 2024 annual accounts show negative equity (-€4,107) and a net result of -€919. The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
- Equity
- -€4,107
- Loss
- -€919
- Bankruptcy chance 12 m
- 19.1%
- Parent
- eureKASYNBIO · 100%
Signals- Annual accounts: weaker financial profile- Limited track record- No NACE activity registered- Higher-failure-rate region- Negative equityFiled after the deadlineShow the evidence
Checked score
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 2 accounts on average 61 days after the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (1)
- Annual accounts filedfiscal year 2024 · full…
- Annual accounts filedfiscal year 2023 · full…
Financials
Fiscal year 2024Total assets €0Loss -€919Equity -€4,107Liquidity 0.00
Financials · fiscal year 2024, full schema
Trend over the years
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.
Result per fiscal year
Key figures and ratios
Filed annual accounts
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Goods, raw materials, services and sundry goods60/61 | €3,128 | €720 | ▼ 77.0% |
| Other operating charges640/8 | - | €238 | - |
| Gross operating margin9900 | -€3,128 | -€720 | ▲ 77.0% |
| Operating profit (loss)9901 | -€3,128 | -€959 | ▲ 69.4% |
| Financial income75/76B | - | €40 | - |
| Recurring financial income75 | - | €40 | - |
| Financial charges65/66B | €60 | €0 | ▼ 100% |
| Recurring financial charges65 | €60 | €0 | ▼ 100% |
| Profit (loss) for the period before taxes9903 | -€3,188 | -€919 | ▲ 71.2% |
| Profit (loss) for the period9904 | -€3,188 | -€919 | ▲ 71.2% |
| Profit (loss) for the period to be appropriated9905 | -€3,188 | -€919 | ▲ 71.2% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €279 | €0 | ▼ 100% |
| Current assets29/58 | €279 | €0 | ▼ 100% |
| Amounts receivable within one year40/41 | €238 | €0 | ▼ 100% |
| Other amounts receivable41 | €238 | €0 | ▼ 100% |
| Cash at bank and in hand54/58 | €0 | €0 | - |
| Deferred charges and accrued income490/1 | €41 | €0 | ▼ 100% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €279 | €0 | ▼ 100% |
| Equity10/15 | -€3,188 | -€4,107 | ▼ 28.8% |
| Contributions10/11 | €0 | €0 | - |
| Profit (loss) carried forward14 | -€3,188 | -€4,107 | ▼ 28.8% |
| Amounts payable17/49 | €3,467 | €4,107 | ▲ 18.5% |
| Amounts payable within one year42/48 | €3,447 | €4,087 | ▲ 18.6% |
| Financial debts43 | €81 | €0 | ▼ 100% |
| Credit institutions430/8 | €81 | €0 | ▼ 100% |
| Trade debts44 | €0 | €0 | - |
| Suppliers440/4 | €0 | €0 | - |
| Other amounts payable47/48 | €3,366 | €4,087 | ▲ 21.4% |
| Accrued charges and deferred income492/3 | €20 | €20 | = |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€3,188 | -€919 | ▲ 71.2% |
| Operating cash flow (approximation) | -€3,188 | -€919 | ▲ 71.2% |
| Change in cash | - | €0 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Board & ownership
Parent eureKASYNBIO · 100%
Directors
Structure & network
Owners and holdings
1 ownerChain of control
- eureKASYNBIO
- Dirac Biosciences
Highest known parent: eureKASYNBIO. The sources do not say who stands above it.
Owners 1
- eureKASYNBIOparent100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 2 Gazette acts processed.
Timeline
2 eventsLatest 26-09-2025
History
Acts, filings and financial milestones
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Company details
Private limited company · founded 12-01-2023Year ends 31-12Peppol not found1 site
Register details
No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.
What can you do?
Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.
If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if electronically, with their agreement on a secure alternative. That invoice is valid; the customer risks a penalty. FPS Finance
If you follow this company, Checked tells you the day it appears in the Peppol register.
Register as of 1 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Sites & property
1 establishment unit
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21822R0227/00V003 | Brussels | 2,791 m² | 1 · 1,235 m² | 106.8 m · 30 fl. |
Linked by address, not proof of ownership
Go further with this company
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.